Implication of hepatokines in metabolic disorders and cardiovascular diseases
- Authors
- Jung, Tae Woo; Yoo, Hye Jin; Choi, Kyung Mook
- Issue Date
- 6월-2016
- Publisher
- ELSEVIER
- Keywords
- Hepatokine; Fetuin-A; Fibroblast growth factor 21; Selenoprotein P; Angiopoietin-like protein 4; Leukocyte cell-derived chemotaxin 2
- Citation
- BBA CLINICAL, v.5, pp.108 - 113
- Indexed
- SCOPUS
- Journal Title
- BBA CLINICAL
- Volume
- 5
- Start Page
- 108
- End Page
- 113
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/88407
- DOI
- 10.1016/j.bbacli.2016.03.002
- ISSN
- 2214-6474
- Abstract
- The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases. (C) 2016 The Authors. Published by Elsevier B.V.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.